United States Biotechnology & Medical Research

Corbus Pharmaceuticals Holdings Inc (CRBP)

Track

Track

Corbus Pharmaceuticals recorded eleven insider trading transactions recently. Executives initiated significant planned sales totaling over $900,000, while Chief Business Officer Nishant C. Saxena purchased shares worth approximately $25,000. These activities follow a recent earnings report where the company missed EPS expectations by nearly 40 percent, despite a 51.9 percent stock price increase over the last quarter.
Ticker: CRBP Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Corbus Pharmaceuticals Holdings Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Saxena Nishant C Chief Business Officer Officer
Transaction date
Purchase
Price
266.17
Quantity 98,850 -29.6%
Value US$1,993,208
4.1
Cohen Yuval Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
219.76
Quantity 65,804 -42.0%
Value US$1,911,693
2.3
Moran Sean F. Chief Financial Officer Officer
Transaction date
Planned sale
Price
468.88
Quantity 38,636 -8.2%
Value US$1,142,347
2.9
Smethurst Dominic Officer Officer
Transaction date
Proposed sale
Price
9.20
Quantity 23,025
Value US$211,818
2.1
Jenkins John Kenneth Non-Executive Director
Transaction date
Planned sale
Price
7.91
Quantity 4,800 -55.6%
Value US$37,986
2.1
Jenkins John Kenneth Non-Executive Director
Transaction date
Planned sale
Price
7.91
Quantity 4,800 -55.6%
Value US$37,986
Altmeyer Anne Non-Executive Director
Transaction date
Planned sale
Price
7.91
Quantity 2,412 -24.1%
Value US$19,088
Altmeyer Anne Non-Executive Director
Transaction date
Planned sale
Price
7.91
Quantity 2,412 -24.1%
Value US$19,088
Kung Winston Non-Executive Director
Transaction date
Planned sale
Price
7.91
Quantity 2,026 -14.3%
Value US$16,033
Saxena Nishant C Chief Business Officer Officer
Transaction date
Purchase
Price
7.58
Quantity 9,000 +13.6%
Value US$68,220
Saxena Nishant C Chief Business Officer Officer
Transaction date
Purchase
Price
7.33
Quantity 4,500 +7.3%
Value US$32,998
2.9
Smethurst Dominic Chief Medical Officer Officer
Transaction date
Sale
Price
8.30
Quantity 6,097 -6.4%
Value US$50,601
2.9
Smethurst Dominic Officer Officer
Transaction date
Proposed sale
Price
8.30
Quantity 6,097
Value US$50,601
1.9
Hodgson Ian Chief Operating Officer Officer
Transaction date
Sale
Price
7.38
Quantity 847 -1.6%
Value US$6,253
2.3
Moran Sean F. Chief Financial Officer Officer
Transaction date
Planned sale
Price
7.78
Quantity 4,701 -4.6%
Value US$36,588
4.1
Cohen Yuval Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
7.78
Quantity 13,871 -7.4%
Value US$107,952
4.1
Cohen Yuval Officer Officer
Transaction date
Proposed sale
Price
40.63
Quantity 20,000
Value US$812,600
2.9
Smethurst Dominic Chief Medical Officer Officer
Transaction date
Sale
Price
8.09
Quantity 3,285 -3.3%
Value US$26,575
1.9
Hodgson Ian Chief Operating Officer Officer
Transaction date
Sale
Price
8.09
Quantity 2,415 -4.4%
Value US$19,537
4.1
Cohen Yuval Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
17.14
Quantity 8,973 -6.1%
Value US$153,797
4.1
Cohen Yuval Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
17.01
Quantity 18,660 -11.9%
Value US$317,407
2.3
Moran Sean F. Chief Financial Officer Officer
Transaction date
Planned sale
Price
17.02
Quantity 12,981 -15.0%
Value US$220,937
4.1
Cohen Yuval Officer Officer
Transaction date
Proposed sale
Price
17.01
Quantity 27,633
Value US$469,977
2.3
Moran Sean F. Officer Officer
Transaction date
Proposed sale
Price
17.02
Quantity 12,981
Value US$220,922
Altmeyer Anne Non-Executive Director
Transaction date
Planned sale
Price
20.50
Quantity 1,060 -14.6%
Value US$21,730
2.1
Jenkins John Kenneth Non-Executive Director
Transaction date
Planned sale
Price
7.35
Quantity 2,783 -98.8%
Value US$20,465
Altmeyer Anne Non-Executive Director
Transaction date
Planned sale
Price
7.25
Quantity 1,392 -50.0%
Value US$10,096
2.9
Smethurst Dominic Chief Medical Officer Officer
Transaction date
Sale
Price
6.78
Quantity 6,393 -8.3%
Value US$43,330
2.9
Smethurst Dominic Officer Officer
Transaction date
Proposed sale
Price
6.84
Quantity 6,393
Value US$43,728
2.3
Moran Sean F. Chief Financial Officer Officer
Transaction date
Planned sale
Price
8.76
Quantity 2,792 -3.7%
Value US$24,446
4.1
Cohen Yuval Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
8.76
Quantity 7,134 -4.9%
Value US$62,465
2.3
Moran Sean F. Officer Officer
Transaction date
Proposed sale
Price
9.48
Quantity 2,792
Value US$26,468
4.1
Cohen Yuval Officer Officer
Transaction date
Proposed sale
Price
9.48
Quantity 7,134
Value US$67,630
CATLIN AVERY W Director Non-Executive Director
Transaction date
Proposed sale
Price
56.43
Quantity 888
Value US$50,109
2.3
Moran Sean F. Chief Financial Officer Officer
Transaction date
Planned sale
Price
42.12
Quantity 1,958 -3.9%
Value US$82,479
4.1
Cohen Yuval Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
42.24
Quantity 7,179 -8.5%
Value US$303,219
4.1
Cohen Yuval Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
42.24
Quantity 2,322 -2.7%
Value US$98,074
4.1
Cohen Yuval Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
42.24
Quantity 1,770 -2.1%
Value US$74,759
4.1
Cohen Yuval Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
42.24
Quantity 11,667 -12.1%
Value US$492,779
2.3
Moran Sean F. Chief Financial Officer Officer
Transaction date
Planned sale
Price
46.77
Quantity 6,730 -12.2%
Value US$314,789
4.1
Cohen Yuval Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
46.02
Quantity 1,770 -2.1%
Value US$81,456
4.1
Cohen Yuval Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
46.02
Quantity 9,333 -10.0%
Value US$429,507
2.3
Moran Sean F. Chief Financial Officer Officer
Transaction date
Planned sale
Price
49.87
Quantity 7,788 -13.8%
Value US$388,417
2.3
Moran Sean F. Chief Financial Officer Officer
Transaction date
Planned sale
Price
49.87
Quantity 1,567 -3.1%
Value US$78,152
4.1
Cohen Yuval Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
50.17
Quantity 12,487 -12.9%
Value US$626,425
4.1
Cohen Yuval Chief Executive Officer Executive Director
Transaction date
Planned sale
Price
50.17
Quantity 16,830 -16.6%
Value US$844,297
2.3
Moran Sean F. Officer Officer
Transaction date
Proposed sale
Price
52.89
Quantity 18,043
Value US$954,294
4.1
Cohen Yuval Officer Officer
Transaction date
Proposed sale
Price
52.89
Quantity 63,358
Value US$3,351,004
Brake Rachael Louise Former Chief Scientific Officer Officer
Transaction date
Proposed sale
Price
40.83
Quantity 15,550
Value US$634,876
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-12 2026-08-11 B Purchase
Saxena Nishant C

Chief Business Officer

Officer
98,850 -29.6%
266.17
US$1,993,208 		98,850 -29.6% 266.17 US$1,993,208
2026-08-10 2026-08-07 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
65,804 -42.0%
219.76
US$1,911,693 		65,804 -42.0% 219.76 US$1,911,693
2026-08-10 2026-08-07 PlS Planned sale
2.3
Moran Sean F.

Chief Financial Officer

Officer
38,636 -8.2%
468.88
US$1,142,347 		38,636 -8.2% 468.88 US$1,142,347
2026-08-07 2026-08-07 PrS Proposed sale
Stifel, Nicolaus & Company, Inc CIAS /FA

Officer

Officer
12,000
10.08
US$120,971 		12,000 10.08 US$120,971
2026-08-07 2026-08-07 PrS Proposed sale
Stifel, Nicolaus & Company, Inc CIAS /FA

Officer

Officer
17,000
10.08
US$171,396 		17,000 10.08 US$171,396
2026-07-27 2026-07-27 PrS Proposed sale
2.9
Smethurst Dominic

Officer

Officer
23,025
9.20
US$211,818 		23,025 9.20 US$211,818
2026-06-11 2026-06-10 PlS Planned sale
2.1
Jenkins John Kenneth
Non-Executive Director
4,800 -55.6%
7.91
US$37,986 		4,800 -55.6% 7.91 US$37,986
2026-06-11 2026-06-10 PlS Planned sale
2.1
Jenkins John Kenneth
Non-Executive Director
4,800 -55.6%
7.91
US$37,986 		4,800 -55.6% 7.91 US$37,986
2026-06-11 2026-06-10 PlS Planned sale
Altmeyer Anne
Non-Executive Director
2,412 -24.1%
7.91
US$19,088 		2,412 -24.1% 7.91 US$19,088
2026-06-11 2026-06-10 PlS Planned sale
Altmeyer Anne
Non-Executive Director
2,412 -24.1%
7.91
US$19,088 		2,412 -24.1% 7.91 US$19,088
2026-06-11 2026-06-10 PlS Planned sale
Kung Winston
Non-Executive Director
2,026 -14.3%
7.91
US$16,033 		2,026 -14.3% 7.91 US$16,033
2026-06-03 2026-06-03 B Purchase
Saxena Nishant C

Chief Business Officer

Officer
9,000 +13.6%
7.58
US$68,220 		9,000 +13.6% 7.58 US$68,220
2026-06-03 2026-06-02 B Purchase
Saxena Nishant C

Chief Business Officer

Officer
4,500 +7.3%
7.33
US$32,998 		4,500 +7.3% 7.33 US$32,998
2026-03-04 2026-03-02 S Sale
2.9
Smethurst Dominic

Chief Medical Officer

Officer
6,097 -6.4%
8.30
US$50,601 		6,097 -6.4% 8.30 US$50,601
2026-03-02 2026-03-02 PrS Proposed sale
2.9
Smethurst Dominic

Officer

Officer
6,097
8.30
US$50,601 		6,097 8.30 US$50,601
2026-02-18 2026-02-17 S Sale
1.9
Hodgson Ian

Chief Operating Officer

Officer
847 -1.6%
7.38
US$6,253 		847 -1.6% 7.38 US$6,253
2026-02-18 2026-02-13 PlS Planned sale
2.3
Moran Sean F.

Chief Financial Officer

Officer
4,701 -4.6%
7.78
US$36,588 		4,701 -4.6% 7.78 US$36,588
2026-02-18 2026-02-13 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
13,871 -7.4%
7.78
US$107,952 		13,871 -7.4% 7.78 US$107,952
2026-02-13 2026-02-13 PrS Proposed sale
4.1
Cohen Yuval

Officer

Officer
20,000
40.63
US$812,600 		20,000 40.63 US$812,600
2026-02-04 2026-02-03 S Sale
2.9
Smethurst Dominic

Chief Medical Officer

Officer
3,285 -3.3%
8.09
US$26,575 		3,285 -3.3% 8.09 US$26,575
2026-02-04 2026-02-03 S Sale
1.9
Hodgson Ian

Chief Operating Officer

Officer
2,415 -4.4%
8.09
US$19,537 		2,415 -4.4% 8.09 US$19,537
2025-12-15 2025-12-11 S Sale
3.7
Cormorant Asset Management, LP
Large shareholder
30,029 -1.3%
11.46
US$344,012 		30,029 -1.3% 11.46 US$344,012
2025-10-27 2025-10-27 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
8,973 -6.1%
17.14
US$153,797 		8,973 -6.1% 17.14 US$153,797
2025-10-27 2025-10-24 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
18,660 -11.9%
17.01
US$317,407 		18,660 -11.9% 17.01 US$317,407
2025-10-27 2025-10-24 PlS Planned sale
2.3
Moran Sean F.

Chief Financial Officer

Officer
12,981 -15.0%
17.02
US$220,937 		12,981 -15.0% 17.02 US$220,937
2025-10-24 2025-10-24 PrS Proposed sale
4.1
Cohen Yuval

Officer

Officer
27,633
17.01
US$469,977 		27,633 17.01 US$469,977
2025-10-24 2025-10-24 PrS Proposed sale
2.3
Moran Sean F.

Officer

Officer
12,981
17.02
US$220,922 		12,981 17.02 US$220,922
2025-10-21 2025-10-20 PlS Planned sale
Altmeyer Anne
Non-Executive Director
1,060 -14.6%
20.50
US$21,730 		1,060 -14.6% 20.50 US$21,730
2025-06-02 2025-05-30 PlS Planned sale
2.1
Jenkins John Kenneth
Non-Executive Director
2,783 -98.8%
7.35
US$20,465 		2,783 -98.8% 7.35 US$20,465
2025-06-02 2025-05-30 PlS Planned sale
Altmeyer Anne
Non-Executive Director
1,392 -50.0%
7.25
US$10,096 		1,392 -50.0% 7.25 US$10,096
2025-03-07 2025-03-06 S Sale
2.9
Smethurst Dominic

Chief Medical Officer

Officer
6,393 -8.3%
6.78
US$43,330 		6,393 -8.3% 6.78 US$43,330
2025-03-06 2025-03-06 PrS Proposed sale
2.9
Smethurst Dominic

Officer

Officer
6,393
6.84
US$43,728 		6,393 6.84 US$43,728
2025-02-18 2025-02-14 PlS Planned sale
2.3
Moran Sean F.

Chief Financial Officer

Officer
2,792 -3.7%
8.76
US$24,446 		2,792 -3.7% 8.76 US$24,446
2025-02-18 2025-02-14 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
7,134 -4.9%
8.76
US$62,465 		7,134 -4.9% 8.76 US$62,465
2025-02-14 2025-02-14 PrS Proposed sale
2.3
Moran Sean F.

Officer

Officer
2,792
9.48
US$26,468 		2,792 9.48 US$26,468
2025-02-14 2025-02-14 PrS Proposed sale
4.1
Cohen Yuval

Officer

Officer
7,134
9.48
US$67,630 		7,134 9.48 US$67,630
2024-09-24 2024-09-20 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
25,769 +1.1%
22.23
US$572,793 		25,769 +1.1% 22.23 US$572,793
2024-09-24 2024-09-20 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
47,564 +2.1%
21.47
US$1,021,389 		47,564 +2.1% 21.47 US$1,021,389
2024-09-24 2024-09-20 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
139,551 +6.5%
20.42
US$2,849,352 		139,551 +6.5% 20.42 US$2,849,352
2024-09-24 2024-09-20 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
66,088 +3.2%
19.61
US$1,296,052 		66,088 +3.2% 19.61 US$1,296,052
2024-09-24 2024-09-20 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
25,943 +1.3%
18.36
US$476,313 		25,943 +1.3% 18.36 US$476,313
2024-09-24 2024-09-20 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
45,085 +2.2%
17.48
US$787,860 		45,085 +2.2% 17.48 US$787,860
2024-09-04 2024-09-04 PrS Proposed sale
CATLIN AVERY W

Director

Non-Executive Director
888
56.43
US$50,109 		888 56.43 US$50,109
2024-06-18 2024-06-18 PlS Planned sale
2.3
Moran Sean F.

Chief Financial Officer

Officer
1,958 -3.9%
42.12
US$82,479 		1,958 -3.9% 42.12 US$82,479
2024-06-18 2024-06-18 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
7,179 -8.5%
42.24
US$303,219 		7,179 -8.5% 42.24 US$303,219
2024-06-18 2024-06-18 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
2,322 -2.7%
42.24
US$98,074 		2,322 -2.7% 42.24 US$98,074
2024-06-18 2024-06-18 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
1,770 -2.1%
42.24
US$74,759 		1,770 -2.1% 42.24 US$74,759
2024-06-18 2024-06-18 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
11,667 -12.1%
42.24
US$492,779 		11,667 -12.1% 42.24 US$492,779
2024-06-18 2024-06-17 PlS Planned sale
2.3
Moran Sean F.

Chief Financial Officer

Officer
6,730 -12.2%
46.77
US$314,789 		6,730 -12.2% 46.77 US$314,789
2024-06-18 2024-06-17 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
1,770 -2.1%
46.02
US$81,456 		1,770 -2.1% 46.02 US$81,456
2024-06-18 2024-06-17 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
9,333 -10.0%
46.02
US$429,507 		9,333 -10.0% 46.02 US$429,507
2024-06-18 2024-06-14 PlS Planned sale
2.3
Moran Sean F.

Chief Financial Officer

Officer
7,788 -13.8%
49.87
US$388,417 		7,788 -13.8% 49.87 US$388,417
2024-06-18 2024-06-14 PlS Planned sale
2.3
Moran Sean F.

Chief Financial Officer

Officer
1,567 -3.1%
49.87
US$78,152 		1,567 -3.1% 49.87 US$78,152
2024-06-18 2024-06-14 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
12,487 -12.9%
50.17
US$626,425 		12,487 -12.9% 50.17 US$626,425
2024-06-18 2024-06-14 PlS Planned sale
4.1
Cohen Yuval

Chief Executive Officer

Executive Director
16,830 -16.6%
50.17
US$844,297 		16,830 -16.6% 50.17 US$844,297
2024-06-14 2024-06-14 PrS Proposed sale
2.3
Moran Sean F.

Officer

Officer
18,043
52.89
US$954,294 		18,043 52.89 US$954,294
2024-06-14 2024-06-14 PrS Proposed sale
4.1
Cohen Yuval

Officer

Officer
63,358
52.89
US$3,351,004 		63,358 52.89 US$3,351,004
2024-05-08 2024-05-08 PrS Proposed sale
Brake Rachael Louise

Former Chief Scientific Officer

Officer
15,550
40.83
US$634,876 		15,550 40.83 US$634,876
2024-03-11 2024-03-08 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
8,862 +0.4%
45.96
US$407,298 		8,862 +0.4% 45.96 US$407,298
2024-03-11 2024-03-08 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
156,597 +8.4%
45.26
US$7,087,580 		156,597 +8.4% 45.26 US$7,087,580
2024-03-11 2024-03-08 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
61,668 +3.4%
44.62
US$2,751,626 		61,668 +3.4% 44.62 US$2,751,626
2024-03-11 2024-03-08 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
18,548 +1.0%
43.26
US$802,386 		18,548 +1.0% 43.26 US$802,386
2024-03-11 2024-03-08 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
24,983 +1.4%
42.25
US$1,055,532 		24,983 +1.4% 42.25 US$1,055,532
2024-03-11 2024-03-08 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
29,342 +1.7%
41.23
US$1,209,771 		29,342 +1.7% 41.23 US$1,209,771
2024-03-11 2024-03-07 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
102,140 +6.3%
41.23
US$4,211,232 		102,140 +6.3% 41.23 US$4,211,232
2024-03-11 2024-03-07 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
90,325 +5.9%
39.99
US$3,612,097 		90,325 +5.9% 39.99 US$3,612,097
2024-03-11 2024-03-07 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
10,736 +0.7%
39.13
US$420,100 		10,736 +0.7% 39.13 US$420,100
2024-03-11 2024-03-07 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
46,799 +3.2%
37.82
US$1,769,938 		46,799 +3.2% 37.82 US$1,769,938
2024-02-06 2024-02-02 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
750,000 +103.4%
19.00
US$14,250,000 		750,000 +103.4% 19.00 US$14,250,000
2024-01-30 2024-01-26 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
3,200 +0.4%
38.49
US$123,168 		3,200 +0.4% 38.49 US$123,168
2024-01-30 2024-01-26 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
43,754 +6.5%
37.49
US$1,640,337 		43,754 +6.5% 37.49 US$1,640,337
2024-01-30 2024-01-26 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
16,484 +2.5%
36.53
US$602,161 		16,484 +2.5% 36.53 US$602,161
2024-01-30 2024-01-26 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
32,295 +5.1%
35.83
US$1,157,130 		32,295 +5.1% 35.83 US$1,157,130
2024-01-30 2024-01-26 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
31,549 +5.3%
34.62
US$1,092,226 		31,549 +5.3% 34.62 US$1,092,226
2024-01-30 2024-01-26 B Purchase
3.7
Cormorant Asset Management, LP
Large shareholder
18,055 +3.1%
33.71
US$608,634 		18,055 +3.1% 33.71 US$608,634
Explore more

More insider trading research around Corbus Pharmaceuticals Holdings Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America